AI Article Synopsis
- Baseline assessment and regular monitoring using patient history, clinical exams, lab tests, and noninvasive imaging can help detect side effects from immune checkpoint inhibitors early.
- The text highlights various cardiotoxic effects linked to immune checkpoint inhibitors, including conditions like pericarditis and myocarditis.
- A case study is presented of a middle-aged man with advanced esophageal cancer who experienced acute heart failure due to nivolumab-induced cardiotoxicity, despite having no prior heart issues or significant risk factors.
Article Abstract
Key Clinical Message: Baseline assessment and interval monitoring with a careful history, clinical examination, laboratory work-up, and noninvasive imaging modalities may be beneficial for early detection of immune checkpoint inhibitor-associated side effects.
Abstract: Previous reports of immune checkpoint inhibitors' cardiotoxic effects include pericarditis, myocarditis, myocardial infarction, ventricular dysfunction, vasculitis, and electrical abnormalities. The authors report a case of acute heart failure caused by nivolumab-induced cardiotoxicity in a middle-aged man with advanced esophageal carcinoma with no previous cardiac history or significant cardiovascular risk factors.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10167613 | PMC |
| http://dx.doi.org/10.1002/ccr3.7306 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Resveratrol amplifies the anti-tumor effect of α-PD-1 by altering the intestinal microbiome and PGD2 content.
Gut Microbes
December 2025
Division of Cancer Biology, Laboratory Animal Center, Fourth Military Medical University, Xi'an, Shaanxi, P.R. China.
The anti-PD-1 mAb may be further considered along with PGD2 or active molecules that can promote PGD2 synthesis to enhance the anti-tumor immune response.
View Article and Find Full Text PDFStatus of a New Model of ERCP Training in China: A Nationwide Survey of Standardized Training for ERCP Procedure (STEP) Programs.
J Clin Gastroenterol
January 2025
Department of Gastroenterology, Changhai Clinical Research Unit, Changhai Hospital.
Aims: ERCP training should adapt to the rapid development of ERCP technology and indications. China has a large population and vast land area, but ERCP training resources are insufficient. To make effective use of scarce ERCP training resources, the Standardized Training for ERCP Procedure (STEP) program was launched as a pilot trial.
View Article and Find Full Text PDFDownregulation of FcRn promotes ferroptosis in herpes simplex virus-1-induced lung injury.
Cell Mol Life Sci
January 2025
School of Basic Medical Sciences, Xinxiang Medical University, #601 Jinsui Road, Xinxiang, 453003, Henan, China.
Herpes simplex virus type I (HSV-1) infection is associated with lung injury; however, no specific treatment is currently available. In this study, we found a significant negative correlation between FcRn levels and the severity of HSV-1-induced lung injury. HSV-1 infection increases the methylation of the FcRn promoter, which suppresses FcRn expression by upregulating DNMT3b expression.
View Article and Find Full Text PDFCorrection for: PTPRD mutation is a prognostic biomarker for sensitivity to ICIs treatment in advanced non-small cell lung cancer.
Aging (Albany NY)
December 2024
Department of Oncology, Jiujiang University Affiliated Hospital, Jiujiang 332000, P.R. China.
NI-3201 Is a Bispecific Antibody Mediating PD-L1-Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control.
Cancer Immunol Res
January 2025
Light Chain Bioscience - Novimmune SA, Geneva, Switzerland.
Despite advances in cancer immunotherapy, such as targeting the PD-1/PD-L1 axis, a substantial number of patients harbor tumors that are resistant or relapse. Selective engagement of T-cell co-stimulatory molecules with bispecific antibodies may offer novel therapeutic options by enhancing signal 1-driven activation occurring via T-cell receptor engagement. In this study, we report the development and preclinical characterization of NI-3201, a PD-L1×CD28 bispecific antibody generated on the κλ-body platform that was designed to promote T-cell activity and antitumor function through a dual mechanism of action.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!